Introduction
============

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduce cardiovascular morbidity and mortality in patients with coronary artery disease (CAD) (secondary prevention), and in individuals at high risk of developing CAD (primary prevention) \[[@R1], [@R2]\]. However, the potential benefits of different statins in patients with chronic heart failure (CHF) remain controversial. Two recent large clinical trials have specifically tested the effect of rosuvastatin in the CHF population, but both yielded disappointing results \[[@R3], [@R4]\]. Whether these results of rosuvastatin studies could be extended to the statin class or other statins is unclear. With regards to atorvastatin, the results of several small randomized controlled trials (RCTs) comparing it with placebo in patients with CHF have been reported \[[@R5]-[@R19]\], but sample-size limitations in these studies prevented any reliable conclusion. Meta-analysis has the potential to increase the power and improve the precision of treatment effects \[[@R20]\]. Therefore, we performed a meta-analysis based on all currently available RCTs to evaluate the clinical efficacy of atorvastatin in patients with CHF.

Material and methods
====================

Data sources and selection criteria
-----------------------------------

To identify relevant trials, the electronic databases (PubMed, EMBASE and the Cochrane Central Register of Controlled Trials) were searched using the following key words: randomized, statin, hydroxymethylglutaryl-CoA reductase inhibitor, atorvastatin, heart failure, cardiac dysfunction. In addition, we scanned conference proceedings from the American College of Cardiology, the American Heart Association, and the European Society of Cardiology. The search was restricted to articles indexed as a clinical trial involving human subjects. The last search was performed in January 2010.

To be selected for this meta-analysis, studies comparing atorvastatin versus placebo treatment in patients with CHF had to be randomized and have their results reported or made available by the trial investigators. All studies meeting the requirements, regardless of the language or form of publication, were considered to be eligible for this meta-analysis. When there were multiple reports from the same trial, we used the most complete and/or recently reported data.

Study outcomes and data abstraction
-----------------------------------

The primary end point was all-cause mortality. Other clinical outcomes of interest included cardiovascular mortality, sudden cardiac death and worsening hospitalization for CHF. Two investigators independently performed data abstraction. In addition to pertinent data on the outcomes of interest, we gathered information on trial names, first author, year of publication, and number of patients enrolled. Disagreements were resolved by consensus.

Statistical analysis
--------------------

Data were managed according to the intention-to-treat principle. Odds ratios (OR) with 95% confidence intervals (CI) were calculated as summary statistics. The pooled OR was calculated with the Mantel-Haenszel method for fixed effects and the DerSimonian and Laird method for random effects \[[@R21], [@R22]\]. To assess heterogeneity across trials, we used Cochran's test and means of the I^2^ statistic \[[@R23]\]. We assessed publication bias with respect to the primary outcomes of interest using a funnel plot as well as the adjusted rank correlation test according to the method of Begg and Mazumdar \[[@R24]\]. A sensitivity analysis was performed by assessing the contribution of individual studies to the summary effect estimate with respect to the primary outcomes. This was done by excluding each trial one at a time and computing meta-analysis estimates for the remaining studies. Results were considered significant at *P* \< 0.05. Statistical analyses were performed with Stata software version 9.0 (Stata Corp, College Station, USA).

Results
=======

Of the 955 potentially relevant articles initially screened, a total of 15 trials that randomly compared atorvastatin therapy with placebo in patients with CHF were initially identified \[[@R5]-[@R19]\]. Eight studies \[[@R5]-[@R12]\] were then excluded due to the prospective crossover design or the lack of data on clinical outcomes. Thus, a total of 7 RCTs were finally included in this meta-analysis, involving 540 patients (296 in the atorvastatin group and 244 controls) \[[@R13]-[@R19]\]. The main characteristics of these trials are displayed in Table [I](#TI){ref-type="table"} and the main baseline characteristics of enrolled patients in individual trials are shown in Table [II](#TII){ref-type="table"}.

The primary endpoint, all-cause mortality, was reported in all 7 trials. As shown in Figure [1](#F1){ref-type="fig"}, there was a significant decrease in all-cause mortality with atorvastatin therapy compared with placebo by the fixed-effect model (6.4% vs. 14.8%, OR 0.39, 95% CI 0.21-0.71, *P* = 0.002). There was no significant heterogeneity between trials (*P* = 0.58, I^2^ = 0%). No evidence of publication bias with respect to all-cause mortality was found using the Begg funnel plot and rank correlation test (*P* = 1.0). Omission of individual trials from the analysis did not have any relevant influence on the overall results.

Both cardiovascular mortality and sudden cardiac death were reported in 5 trials. During the follow-up period, the risks of cardiovascular mortality (5.5% vs. 16.8%, OR 0.28, 95% CI 0.12-0.63, *P* = 0.002; *P* = 0.63, I^2^ = 0% for heterogeneity) and sudden cardiac death (2.4% vs. 10.1%, OR 0.24, 95% CI 0.08-0.71, *P* = 0.01; *P* = 0.75, I^2^ = 0% for heterogeneity) in patients with atorvastatin therapy were also significantly lower than those in the controls by the fixed-effect model.

Hospitalization for worsening CHF was reported in 6 trials. As shown in Figure [2](#F2){ref-type="fig"}, there was a significant decrease in hospitalization for worsening CHF with atorvastatin therapy compared with placebo by the fixed-effect model (10.4% vs. 25.4%, OR 0.30, 95% CI 0.18-0.52, *P* \< 0.001). There was no significant heterogeneity between trials (*P* = 0.76, I^2^ = 0%).

Discussion
==========

By pooling all currently available RCTs which reported clinical effects of atorvastatin in patients with CHF, the present meta-analysis showed that atorvastatin was associated with significantly decreased risks of all-cause mortality, cardiovascular mortality, sudden cardiac death and hospitalization for worsening CHF, as compared with placebo.

Statins are widely known as therapeutic agents for hypercholesterolaemia. Recently, evidence of their pleiotropic effects, meaning outside of the ability to reduce cholesterol levels, has emerged. The potent pleiotropic effects of statins, including potential benefits for myocardial cellular function, down-regulation of tissue renin-angiotensin-aldosterone system activation, restoration of autonomic function, neoangiogenesis, and inhibition of proinflammatory cytokines, could favourably influence the natural history of CHF \[[@R25]-[@R30]\]. Statins possess anti-inflammatory effects and decrease vascular cell adhesion molecule-1 levels in CHF.31 Additionally, circulating lipids have the capacity to detoxify bacterial lipopolysaccharides, which stimulate the release of inflammatory cytokines in CHF \[[@R32]\]. Taken together, the rationale supporting the potential benefits of statin therapy in CHF is well grounded \[[@R33], [@R34]\].

The first indirect information about the beneficial effects of statins in CHF came from the post hoc analyses of a landmark clinical trial of statin therapy. In the Scandinavian Simvastatin Survival Study (4S) \[[@R35]\], patients who had known CAD and hypercholesterolaemia were included. A lower incidence of symptomatic CHF was observed in the simvastatin group, compared with the placebo group. Also, there was a 19% relative risk reduction in 5-year mortality with statin therapy in patients who had CHF. Additionally, the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) \[[@R36]\] trial observed a mortality benefit of pravastatin in CHF (*P* \< 0.05), while the Heart Protection Study (HPS) \[[@R37]\] showed a marginal reduction in mortality (3.4% in simvastatin vs. 3.9% in placebo group) and hospitalization. The A to Z trial \[[@R38]\] showed reduction of new-onset CHF by 18% (*P* \< 0.05).

Recently, data from large observational studies were consistent in showing a beneficial effect of statins in patients with CHF \[[@R39]-[@R44]\]. The retrospective trial by Foody *et al.* \[[@R39]\] evaluated statin therapy in patients admitted to acute care hospitals with a principal diagnosis of CHF. A sample of 54 960 patients, all more than 65 years of age, was analysed. Patients who received statins on discharge (16.7%) were shown to have significant reductions in 1-year mortality by 20% (*P* \< 0.001) and 3-year mortality by 18% (*P* \< 0.001), even after adjustment for clinical confounders. However, these patients also had higher rates of cardiac investigations, were more likely to be seen by a cardiologist and received a higher rate of concomitant aspirin, beta-blockers and angiotensin-converting enzyme inhibitor prescriptions on discharge. Another large observational cohort study by Go *et al.* \[[@R40]\] involved 24 598 adults diagnosed with CHF who had no prior statin use. Using an intent-to-treat approach, incident statin use was associated with a 21% (*P* \< 0.001) and 24% (*P* \< 0.001) reduction in hospitalization for CHF and total mortality, respectively. It is important to note that statins were more likely to be prescribed in younger patients and those known to have CAD, diabetes, or hypertension in this study. A pre-specified post hoc analysis of the TNT trial (80 vs. 10 mg/d atorvastatin, *n* = 10 001 with CAD) showed that intensive treatment with atorvastatin in patients with stable coronary disease significantly reduces subsequent hospitalizations for CHF compared with low-dose therapy (2.4% vs. 3.3%, *P* = 0.0116) \[[@R43]\]. Moreover, this benefit was most pronounced in patients with a history of CHF (41% lower, *P* = 0.008), while in patients without a history of CHF, hospitalization rates for CHF were similar in the high- and low-dose atorvastatin groups.

Contrary to the previously mentioned reports of benefit with statin therapy, two large, prospective randomized trials with robust clinical end points present conflicting data. The CORONA trial \[[@R3]\] assessed the effectiveness and safety of rosuvastatin 10 mg versus placebo in addition to optimal CHF treatment in prevalent symptomatic CHF cases, with a history of myocardial infarction and not previously treated with a statin. The study reported no effect on all-cause mortality and hospitalization over the median follow-up period of 32 months (HR 0.95; *P* = 0.31), though safety of the statin was demonstrated. With regards to the reasons why CORONA did not show the expected benefits, one possibility is the study population (CORONA included elderly subjects \[mean age 73 years; 41% were older than 75 years\] with severe systolic CHF, and 61% of the CHF population was New York Heart Association \[NYHA\] class III with a mean ejection fraction of 31%). It is possible that rosuvastatin was administered too late in the natural course of CHF to show a benefit. Another explanation is that patients in the CORONA study were receiving almost optimal background treatment for CHF (most patients were on a renin-angiotensin-aldosterone system \[RAAS\] blocker \[91%\], a loop or thiazide diuretic \[89%\], a beta-blocker \[75%\], and antiplatelet or anticoagulant therapy \[90%\]). Therefore, it might be that the CORONA population was "too well treated" to achieve an additional benefit from statins. The GISSI-HF trial \[[@R4]\] enrolled patients aged 18 years or older with symptomatic CHF of ischaemic and non-ischaemic cause, randomly assigned them to rosuvastatin 10 mg daily or placebo, and followed them up for a median of 3.9 years. No effect was seen in all-cause mortality or combined mortality and hospital admissions (HR 1.0 and 1.1, respectively). The GISSI-HF trial differed from the CORONA trial in some aspects of the population enrolled (lower proportion with ischaemic aetiology, younger age, and less severe symptoms). However, patients in the GISSI-HF study were also receiving optimal background treatment for CHF and might be "too well treated" to achieve an additional benefit from statins. Moreover, it remains possible that benefits of statins may be offset by a negative impact of cholesterol lowering in CHF patients, as some evidence suggests that low serum total cholesterol is associated with a marked increase in mortality in advanced CHF.

Although there is overwhelming evidence that statins are equally effective for primary and secondary prevention of cardiovascular disease, statins may differ in their properties in patients with CHF and most of the studies with favourable outcomes used drugs other than rosuvastatin. Likewise, the present meta-analysis found that atorvastatin could significantly decrease risks of all-cause mortality, cardiovascular mortality, sudden cardiac death and hospitalization for worsening symptoms as compared to placebo in patients with CHF. One of the differences between atorvastatin and rosuvastatin is lipophilicity. Atorvastatin is more lipophilic than rosuvastatin and may penetrate the cell membrane more effectively, which could provide a theoretical advantage \[[@R45]\]. Moreover, lipophilic statins may be superior to hydrophilic statins in preventing cardiovascular events because of their potent pleiotropic effects such as the inhibition of pro-inflammatory cytokine production or matrix metalloproteinase expression \[[@R46], [@R47]\]. These results suggested that different statins may have inconsistent benefits regarding important clinical consequences of CHF. Thus, the fact that a unique statin agent (rosuvastatin) was used in CORONA and GISSI-HF trials might be one of the causes of their negative results, which could not be automatically extrapolated to other statins.

Our results suffer from those limitations which are inherent to all meta-analytic techniques, including particularly heterogeneity in patient populations, different study drug regimens, and variable endpoint definitions and follow-up periods across studies. In particular, in this analysis we used aggregate data as reported or calculated in published articles, rather than data of individual patients. Furthermore, although there was no statistical heterogeneity in our analysis, the number of patients is very small overall and also in each trial, and the number of events is very small. Given the mean small sample size of the studies included in our study, our findings should be interpreted with caution. Further large, well-conducted randomized trials are needed to confirm the benefits of atorvastatin or other statins for CHF relative to placebo or rosuvastatin.
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###### 

Main characteristics of the trials included in the meta-analysis

  Study                          Year of publication   *N*   Dose of atorvastatin \[mg/day\]   Inclusion criteria                                                    Primary endpoints                                 Follow-up \[months\]
  ------------------------------ --------------------- ----- --------------------------------- --------------------------------------------------------------------- ------------------------------------------------- ----------------------
  Hamaad A, *etal*.              2005                  23    40                                Stable systolic CHF, LVEF \< 45%                                      Heart rate variability                            3
  Sola S, *et al*.               2006                  108   20                                Stable non-ischaemic CHF, LVEF\< 35%                                  Change in LVEF                                    12
  Wojnicz R, *et al*.            2006                  74    40                                Stable CHF secondary to inflammatory DC                               LVEF and NYHA class                               6
  Yamada T, *et al*.             2007                  38    10                                Mild to moderate CHF, LVEF \< 40%                                     LVEF and BNP                                      31
  Vrtovec B, *etal*.             2008                  110   10                                Stable systolic CHF, LVEF \< 30% and total cholesterol \> 150 mg/dl   Sudden cardiac death                              12
  Xie RQ, *et al*.               2008                  119   10-20                             IschaemicCHF, LVEF \< 45%                                             QTc, QTcd, and LVEF                               12
  Bielecka-Dabrowa A, *et al*.   2009                  68    40                                DC with LVEF \< 40%                                                   nflammatory markers, LVEF, and undesired events   6

*CHF -- chronic heart failure, LVEF -- left ventricular ejection fraction, DC -- dilated cardiomyopathy, BNP -- brain natriuretic peptide, QTc -- heart rate-corrected QT interval, QTcd -- heart rate-corrected QT dispersion*

###### 

Baseline clinical and angiographic characteristics of the study population

  Trial                                     Hamaad A, *et al*             Sola S, *et al*             Wojnicz R, *et al*.              YamadaT, *etal*              Vrtovec B, *et al*             XieRQ etal.               Bielecka-Dabrowa A *et al*   
  ----------------------------------------- ------------------- --------- ----------------- --------- --------------------- ---------- ----------------- ---------- -------------------- --------- ------------- ----------- ---------------------------- -----------
  Age \[year\]                              68 +10              66 +10    53 +6             54 +7     37 +11                39 +10     63 +9             68 +8      62 +16               64 +8     --            --          56 ±10                       59 +14
  Male, *n (%)*                             11 (92)             7(78)     34 (64)           33 (62)   28 (78)               32 (84)    14 (74)           16 (84)    35 (64)              32 (58)   --            --          38 (93)                      20 (74)
  Diabetes mellitus, *n (%)*                ^---^               ^---^     ^---^             ^---^     ^---^                 ^---^      4(22)             4(22)      ^---^                ^---^     --            --          8 (19)                       7(25)
  Cigarette smoking, *n (%)*                ^---^               ^---^     ^---^             ^---^     ^---^                 ^---^      9(47)             5(26)      ^---^                ^---^     --            --          3 (7)                        4(15)
  Body mass index \[kg/m2\]                 ^---^               ^---^     24 +4             24 +4     30 +4                 29 +5      23 +2             23 +4      ^---^                ^---^     --            --          29.1 ±5.0                    24.8 +3.5
  Low-density lipoprotein \[mg/dl\]         150 +58             119 +38   118 +15           124 +20   166 +19               158 +35    119 +27           118 +45    95 +7                96 +7     139 ±21       142 ±21     122 ±34                      112 +34
  NYHA class                                                                                                                                                                                                                                              
  1                                         --                  --        --                --        --                    --         3(16)             3(16)      --                   --        --            --          3 (8)                        5(19)
  II                                        7(58)               8 (89)    16 (30)           14 (26)   26 (72)               27 (71)    13 (68)           13 (68)    --                   --        --            --          18 (45)                      9(33)
  III                                       5(42)               1(H)      35 (64)           38 (70)   10 (28)               11 (29)    1(6)              1(6)       --                   --        --            --          19 (47)                      13 (48)
  IV                                        --                  --        3(6)              2(4)      --                    --         --                --         --                   --        --            --          --                           --
  LVEF \[%\]                                28 +7               34+7      33 +5             33 +4     27 +7                 29 +7      28 +10            27 +8      25 +4                24 +5     38.6 ±3.7     38.4 ±3.6   30.3 ±7.4                    27.1 +7.5
  **P**-blocker therapy, *n (%)*            9(75)               8 (89)    36 (67)           39 (72)   36 (100)              38 (100)   16 (84)           13 (68)    44 (80)              45 (82)   --            --          37 (90)                      22 (85)
  ACEI or ARB therapy, *n (%)*              12 (100)            9 (100)   46 (85)           49 (91)   36 (100)              38 (100)   18 (95)           19 (100)   54 (98)              51 (93)   --            --          39 (95)                      25 (93)
  Aldosterone antagonist therapy, *n (%)*   --                  --        5(9)              6(11)     36 (100)              38 (100)   --                --         17 (31)              22 (40)   --            --          35 (85)                      25 (93)
  Diuretics therapy, *n (%)*                12 (100)            9 (100)   35 (65)           35 (65)   36 (100)              38 (100)   17 (89)           16 (83)    50 (91)              49 (89)   --            --          37 (90)                      26 (96)

*LVEF -- left ventricular ejection fraction, NYHA -- New York Heart Association, ACEI -- angiotensin-converting enzyme inhibitors, ARB -- angiotensin II receptor blocker Baseline*
